The earnings call highlighted significant progress in the commercial launch of Symvess, with expanded hospital approvals and strong sales momentum. However, challenges such as the denial of CMS NTAP application and the impact of public attacks on the approval process were noted. The company is taking proactive measures to maintain financial stability and continue its growth trajectory.

Company Guidance -

Q3 2025

During the Humacyte Second Quarter 2025 Results Conference Call, comprehensive guidance was provided highlighting significant progress and financial metrics. The company announced that a total of 13 organizations had completed the Value Analysis Committee (VAC) process, allowing 82 civilian hospitals to purchase Symvess, a substantial increase from just 5 hospitals in the last quarter. Additionally, Symvess received electronic catalog (ECAT) listing approval from the U.S. Defense Logistics Agency, making it available to 35 military treatment facilities and 160 U.S. Department of Veterans Affairs hospitals. Commercially, July sales of approximately $0.3 million surpassed total sales for the first half of the year. The company reported $0.3 million in revenue for Q2 2025 and implemented a workforce reduction plan, resulting in an estimated savings of $50 million over 2025 and 2026. Despite the Centers for Medicare and Medicaid Services declining the new technology add-on payment for Symvess, Humacyte remains optimistic, as only 4.3% of vascular trauma patients fall within Medicare coverage. They are engaging with private payers for supplemental reimbursement. The company is also advancing its acellular tissue engineered vessel (ATEV) program, with promising results from the V007 Phase III trial and plans to file a supplemental Biologics License Application (BLA) in 2026. Financially, Humacyte reported a net income of $1.5 million for the first half of 2025, a significant improvement from a net loss of $88.6 million in the same period last year, primarily due to the non-cash remeasurement of a contingent earn-out liability.

Expansion of Symvess Approvals

The number of civilian hospitals eligible to purchase Symvess increased from 5 to 82, with an additional 40 VAC sites reviewing the product.

ECAT Listing and First Military Sale

Symvess received ECAT listing approval, allowing sales to 35 military treatment facilities and 160 VA hospitals. The first sale to a U.S. military facility was recorded, followed by a reorder.

Strong Sales Performance

July sales of $0.3 million exceeded total sales for the first half of the year, indicating strong commercial momentum.

V007 Phase III Trial Success

V007 Phase III trial results showed significantly higher functional and secondary patency for ATEV recipients compared to fistula in high-risk patients.

Cost Reduction Initiatives

Implemented workforce reductions and other cost-saving measures, resulting in estimated savings of $3.8 million in 2025 and up to $38 million in 2026.

Humacyte (HUMA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HUMA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 07, 2025	2025 (Q3)	-0.16 / -	-0.33	―	―	―
Aug 11, 2025	2025 (Q2)	-0.16 / -0.24	-0.48	50.00% (+0.24)	―
May 13, 2025	2025 (Q1)	-0.19 / 0.28	-0.29	196.55% (+0.57)	―
Mar 28, 2025	2024 (Q4)	-0.25 / -0.16	-0.24	33.33% (+0.08)	―
Nov 08, 2024	2024 (Q3)	-0.25 / -0.33	-0.25	-32.00% (-0.08)	―
Aug 13, 2024	2024 (Q2)	-0.24 / -0.48	-0.22	-118.18% (-0.26)	―
May 10, 2024	2024 (Q1)	-0.23 / -0.29	-0.36	19.44% (+0.07)	―
Mar 22, 2024	2023 (Q4)	-0.24 / -0.24	-0.04	-500.00% (-0.20)	―
Nov 09, 2023	2023 (Q3)	-0.25 / -0.25	-0.25	0.00% (0.00)	―
Aug 14, 2023	2023 (Q2)	-0.22 / -0.22	0.35	-162.86% (-0.57)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HUMA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$2.48	$1.74	-29.84%
May 13, 2025	$1.32	$1.73	+31.06%
Mar 28, 2025	$2.01	$1.96	-2.49%
Nov 08, 2024	$5.26	$5.78	+9.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Humacyte (HUMA) report earnings?

Humacyte (HUMA) is schdueled to report earning on Nov 07, 2025, Before Open (Confirmed).

What is Humacyte (HUMA) earnings time?

Humacyte (HUMA) earnings time is at Nov 07, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HUMA EPS forecast?

HUMA EPS forecast for the fiscal quarter 2025 (Q3) is -0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing